8、Passaro A, Jänne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2(4):377-391. doi:10.1038/s43018-021-00195-8
Impact of Speci c Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta- Analysis. J...
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC):the road to a success,paved with failures. Lee DH. Pharmacology and Therapeutics . 2017Lee DH.Treatments for EGFR-mutant non-small cell lungcancer (NSCLC) : The road to a success, paved with failures[J]. Pharmacol Therapeut, ...
Third-generation EGFR tyrosine-kinase inhibitors (TKIs) have become the standard-of-care first-line treatment for advanced-stage EGFR-mutant non-small-cell lung cancer (NSCLC). However, their efficacy appears to have plateaued, with the median progression-free survival duration not exceeding 2 years...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). Osimertinib, a mutant selective EGFR TKI, when used as initial therapy, results in median progression free survival (PFS)...
[18]https://blog.dana-farber.org/insight/2021/04/egfr-mutant-lung-cancer-what-you-need-to-know/ ▌ 关于申请 如果您或家人不幸被确诊为重大疾病,并且已从其他信息渠道获悉美国有该病的治疗方案、专家、药物、临床研究等医疗资讯,有意出国寻求医疗救治的或者视频咨询的,我们欢迎您病情相关资料。我们美国总部...
[6]PASSARO A, JANNE P A, MOK T, et al. Overcoming therapy resistance in EGFR-mutant lung cancer [J]. Nat Cancer, 2021, 2(4): 377-91.[7]OFFIN M, CHAN J M, TENET M, et al. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic...
Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR‐ mutant advanced non‐small cell lung cancer. JAMA Oncol. 2018;4(5):739–42. [5] Hang-Ping Yao et al, Progress and challenge in development of ...
[2]Passaro A, Jänne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021 Apr;2(4):377-391. doi: 10.1038/s43018-021-00195-8. Epub 2021 Apr 15. PMID: 35122001. [3] 公开的各药物临床研究文献...
1. Gadgeel S, Cho BC, Lu S, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC: longer follow-up of the MARIPOSA study. Presented at: \ IASLC 2024 World Conference on Lung Cancer; September 7-10, 2024; San Diego, CA. Abstract OA02.03. ...